Latest Posts Under: Pharma Industry News

Boehringer Ingelheim expands pets vaccines production facility in Athens

German pharma giant Boehringer Ingelheim has wrapped up the $76 million expansion of its pets vaccines production facility at Athens in Georgia, US. The investment doubles the capacity of Boehringer Ingelheim to produce vaccines for pets in the US and across the world two times. Expansion of the pets vaccines production plant was announced in […]

SHINE raises capital for medical isotope production facility from Oaktree

SHINE Medical Technologies has secured $50 million financing with funds managed by Oaktree Capital Management to support its upcoming medical isotope production facility and the commercialization of molybdenum-99 (Mo-99), lutetium-177 (Lu-177), and other diagnostic and therapeutic isotopes. Greg Piefer – founder and CEO of SHINE Medical Technologies said:  “Oaktree has broad expertise in complex infrastructure […]

ProTom Radiance 330 proton therapy system bags FDA 510(k) Clearance

ProTom International has been given 510(k) clearance from the US Food and Drug Administration (FDA) for its Radiance 330 proton therapy system installed at the Massachusetts General Hospital (MGH) in Boston. According to the proton therapy technology manufacturer, the installed Radiance 330 proton therapy system is a compact, single-room system, which features an advanced pencil […]

Verastem gets FDA orphan drug status for COPIKTRA for T-Cell lymphoma

Verastem Oncology has secured orphan drug designation for COPIKTRA (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K), from the US Food and Drug Administration (FDA) for the treatment of T-Cell lymphoma. COPIKTRA has FDA approval for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) following more than two prior therapies. The PI3K also has […]

CENTAUR clinical trial of AMX0035 : Amylyx says last patient completes last study visit

Amylyx Pharmaceuticals said that the last enrolled patient in the CENTAUR clinical trial, which is evaluating AMX0035 for amyotrophic lateral sclerosis (ALS), has finished the 24 weeks of study treatment. The CENTAUR clinical study is a randomized, double-blind, placebo-controlled phase 2 clinical trial. The primary goals of the mid-stage clinical trial are to assess the […]

FDA approves AstraZeneca’s FASENRA self-administration via FASENRA Pen

AstraZeneca has bagged approval from the US Food and Drug Administration (FDA) for the self-administration of FASENRA (benralizumab) through FASENRA Pen, a pre-filled, single-use auto-injector, for the add-on maintenance treatment of severe asthma in patients aged 12 years and older, and with an eosinophilic phenotype. FASENRA is a monoclonal antibody which directly binds to the […]

The post FDA approves AstraZeneca’s FASENRA self-administration via FASENRA Pen appeared first on PharmaNewsDaily.com.

Icosavax, a new vaccine development company, launched in Seattle

Icosavax, a new pharma company, focused on developing vaccines against infectious diseases, has been launched in Seattle, Washington. The vaccine development company is backed by $51 million capital raised through a Series A financing round led by Qiming Venture Partners USA. Other investors in Icosavax are Sanofi Ventures, Adams Street Partners, and NanoDimension, alongside continuing […]

The post Icosavax, a new vaccine development company, launched in Seattle appeared first on PharmaNewsDaily.com.

Graybug Vision initiates ALTISSIMO clinical trial for GB-102 in wet AMD

Graybug Vision has initiated the ALTISSIMO clinical trial, a phase 2b study, which will evaluate its pan-VEGF receptor inhibitor GB-102 in patients with wet age-related macular degeneration (wet AMD). Based in California, Graybug Vision is a clinical-stage pharma company engaged in developing drugs for ocular diseases like wet AMD, diabetic macular edema (DME), primary open […]

The post Graybug Vision initiates ALTISSIMO clinical trial for GB-102 in wet AMD appeared first on PharmaNewsDaily.com.

Elicio raises $33m to advance lymph node-targeted immuno-therapies

US immuno-oncology company Elicio Therapeutics has raised $33 million through a Series B financing round to advance ELI-002, an Amphiphile mKRAS vaccine (AMP KRAS), and other lymph node targeted immuno-therapies. Elicio Therapeutics said that it has established an international investor base which includes Clal Biotechnology Industries, Efung Capital, and Livzon Pharmaceutical Group. According to the […]

The post Elicio raises $33m to advance lymph node-targeted immuno-therapies appeared first on PharmaNewsDaily.com.

Scroll To Top